Moderna, Inc. (MRNA)
Moderna's stock pops after biotech ekes out profit and revenue beats by a wide margin
Moderna Inc.'s stock jumped 5% early Thursday, after the company's third-quarter earnings showed an unexpected profit and revenue that beat estimates by a wide margin.
Moderna posts surprise profit as Covid vaccine sales impress, cost cuts take hold
Moderna on Thursday posted a surprise profit for the third quarter, smashing Wall Street estimates, as its cost-cutting efforts took hold and sales of its Covid vaccine came in higher than expected. Moderna said Thursday its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.
Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its COVID-19 vaccine, even with low revenue from its new respiratory syncytial virus shot.
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Moderna, Inc. MRNA will release earnings results for its third quarter, before the opening bell on Thursday, Nov. 7.
Moderna CEO Bancel steps down as sales chief, Bloomberg Law reports
Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief commercial officer, Bloomberg Law reported on Tuesday citing one person familiar with the matter.
Should Moderna Stock Be in Your Portfolio Pre-Q3 Earnings?
When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV vaccine, mResvia.
Analysts Estimate Moderna (MRNA) to Report a Decline in Earnings: What to Look Out for
Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moderna (MRNA) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Moderna (MRNA) closed at $55.22, indicating a +0.77% shift from the previous trading day.
Moderna Stock Price Target Slashed. It's About Vaccines.
The drug maker's shares have dropped 46% so far this year and 56% in the past three months.
Moderna Named a Top Employer by Science for Tenth Consecutive Year
CAMBRIDGE, MA / ACCESSWIRE / October 24, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced it was ranked as a top employer in the global biopharmaceutical industry in Science and Science Careers' 2024 Top Employers Survey for the tenth consecutive year. Moderna was recognized for its commitment to continuous innovation, treating employees with respect, and social responsibility.
We Think Moderna Still Has A Future
Moderna, Inc.'s share price has weakened due to declining COVID-19 vaccine demand, but its diverse asset portfolio supports future growth and returns. The company is focusing on respiratory vaccines, including RSV, Flu, and COVID-19 variants, to sustain and grow its revenue streams. Despite massive R&D expenditures and significant losses, Moderna's development portfolio, including oncology and other vaccines, holds substantial long-term potential.
Why Moderna (MRNA) Dipped More Than Broader Market Today
Moderna (MRNA) reachead $53.80 at the closing of the latest trading day, reflecting a -0.55% change compared to its last close.
